HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.

AbstractUNLABELLED:
The ectopically expressed fibroblast growth factor receptor 3 (FGFR3) and its constitutively active mutations have been detected in patients with multiple myeloma (MM). This study investigated whether the cytotoxic effects of bortezomib on malignant plasma cells are associated with FGFR3 expression and the existence of mutations of FGFR3.
MATERIALS AND METHODS:
Cell apoptosis assays were performed in a plasmacytoma cell line, FR4 cells and a myeloma cell line, RPMI8226 cells overexpressing wild-type FGFR3 (FGFR3(WT)) or two different mutants, FGFR3(K650E) or FGFR3(Y373C), and the induction of endoplasmic reticulum (ER) stress protein was compared between each type of cell.
RESULTS:
FR4 cells with FGFR3(K650E) showed enhanced sensitivity to bortezomib together with increased induction of ER stress proteins, compared to FR4 cells with mock, FGFR3(WT) or FGFR3(Y373C). RPMI8226 cells with FGFR3(K650E) also showed enhanced bortezomib sensitivity.
CONCLUSION:
This study indicated that FGFR3K650E is associated with bortezomib sensitivity in malignant plasma cells via ER stress pathways.
AuthorsMasayasu Otsuka, Masao Mizuki, Jiro Fujita, Sumin Kang, Yuzuru Kanakura
JournalAnticancer research (Anticancer Res) Vol. 31 Issue 1 Pg. 113-22 (Jan 2011) ISSN: 1791-7530 [Electronic] Greece
PMID21273588 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • RNA, Messenger
  • Bortezomib
  • FGFR3 protein, human
  • Receptor, Fibroblast Growth Factor, Type 3
Topics
  • Antineoplastic Agents (therapeutic use)
  • Apoptosis
  • Blotting, Western
  • Boronic Acids (therapeutic use)
  • Bortezomib
  • Drug Resistance, Neoplasm (genetics)
  • Humans
  • Immunoenzyme Techniques
  • Multiple Myeloma (drug therapy, genetics)
  • Plasma Cells (drug effects, metabolism, pathology)
  • Point Mutation
  • Pyrazines (therapeutic use)
  • RNA, Messenger (genetics)
  • Receptor, Fibroblast Growth Factor, Type 3 (genetics, metabolism)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: